This is an analysis of the impact of the ACEI ramipril on stroke, its subtypes, and related disability from the industry-sponsored Heart Outcomes Prevention Evaluation (HOPE) trial, a double-blind ...

[31] The PHARAO trial was a prospective, randomized, controlled study designed to analyze the effect of the angiotensin-converting enzyme inhibitor (ACEI) ramipril on preventing or delaying HTN.

Last month, on October 23, the U.S. Food and Drug Administration (FDA) recalled 112,770 bottles of one popularly prescribed ACE inhibitor, Ramipril, produced by Lupin Pharmaceuticals Inc., a ...

So, should all patients with IgAN and proteinuria above 1 g per day receive combined short-term corticosteroid and long-term ACEI (or angiotensin receptor blocker [ARB]) therapy? In view of the ...